Last updated: October 6, 2021
Sponsor: Hongchang Guo
Overall Status: Active - Recruiting
Phase
4
Condition
Cardiac Surgery
Diabetes Mellitus, Type 2
Diabetes Prevention
Treatment
N/AClinical Study ID
NCT04340908
AZ-SGLT2i
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age ≥ 18 years old at index date.
- Diagnosis of Type 2 Diabetes.
- Scheduled for cardiac surgery (coronary artery bypass grafting, valve replacement,ventricular assist device, cardiac transplantation, or any other surgery requiringthoracotomy).
- eGFR ≥ 60 ml/min/1.73 m2.
- Patients who agree to receive treatment with SGLT2 inhibitors.
- Patients must be on current stable hemodynamic profile , without dehydration.
Exclusion
Exclusion Criteria:
- Diagnosis of Type 1 Diabetes.
- eGFR < 60 ml/min/1.73 m2.
- Unstable or rapidly progressive renal disease.
- Hypersensitivity to dapagliflozin or any excipients.
- Severe hepatic disease.
- Patients who have participated in any other clinical trial of an investigationalmedicinal product within the previous 30 days.
- Any other reason considered by a study physician to be inappropriate for inclusion.
Study Design
Total Participants: 500
Study Start date:
January 01, 2021
Estimated Completion Date:
June 01, 2023
Connect with a study center
Beijing Anzhen Hospital, Capital Mediacal University
Beijing, Beijing 100000
ChinaActive - Recruiting


Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.